drugset / Trial / NCT06630559
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis
Timeline
- Start
- 2025-05-26
- Primary completion
- 2026-02-18
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT-P55 | Monoclonal antibody | 300 mg | Subcutaneous |
| Comparator | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |